Fluticasone/theophylline- Vectura

Drug Profile

Fluticasone/theophylline- Vectura

Alternative Names: ADC 4022/fluticasone; SKP 2075; Theophylline/fluticasone - Vectura

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator Pulmagen Therapeutics
  • Developer Vectura
  • Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Bronchodilators; Corticosteroids; Xanthines
  • Mechanism of Action Glucocorticoid receptor agonists; Histone deacetylase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Aug 2014 Preclinical trials in Chronic obstructive pulmonary disease in Switzerland (Inhalation)
  • 13 Aug 2014 Skyepharma plans a phase II trial for Chronic obstructive pulmonary disease (Inhalation) in Switzerland
  • 13 Aug 2014 Skyepharma acquires fluticasone/theophylline from Pulmagen Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top